您好,欢迎访问三七文档
当前位置:首页 > 医学/心理学 > 药学 > 蛋白多肽类药物体内药代动力学特征及分析方法研究进展
PharmaceuticalBiotechnology2014214363~366*210009、。、、、。、、。、、LC-MS/MS、、。Q516A1005-8915201404-0363-04、、、1。。1、。1.1给药途径iv、sc、im。II2。。、。CellpenetratingpeptidesCPPsHIV-1TatPene-tratinandOligoar-Ginine。Penetratin-1GLP-15%3。1.2体内分布。RGD4。Phagedisplaytechniques-5。Vd1%~10%0.1%6。mPEG-SC20k-HM-3SDVd0.11L/kg、、、、0.5%~5%7。1.3代谢与消除P450、。。Target-mediateddrugdispositionTMDD8。CEATMDD7dCEACEA10CEACEA9。363*2013-11-012014-02-24863“”No.2012AA020304“AP25”SBY201020063“PEGHM-3”No.CXZZ11_0821。E-maila342922096@126.com。*Tel/Fax025-83271007E-mail1037714870@qq.com13913925346@126.com。214T1/2βHM-31820T1/2β20min。PEG、FcT1/2β10-11。HM-3PEGT1/2β20h7。1.4排泄。。AP252525.9、、36h0.1%12。1.5其他1.5.1非线性药代动力学特征、、。、、rh-sc-uPAT1/2β613±118min1115±211min1213±219minAUCivCLS13。1.5.2血浆蛋白结合率较高。、14。HM-3AP2570%。2、、。、、LC-MS/MS。2.1酶联免疫吸附测定ELISAELISA。-、、、。EMEA2007。ELISA。Ding15HAS-BNP2BNPHAS。。-ELISAβ-HCG0.1ng/mL16。ELISAAP25。ELISAAP2520ng/mL97.98%~101.07%12。ELISADNART-PCRDNA。PCR3~417。ELISA。HPLCLC-MSELISA。RobertELISA2DLC/MS-1GLP-1、GLP-1N、GLP-1CGLP-118。2.2放射性同位素示踪技术、、。125I3H125I。19T125IADWX-1125I-ADWX-1。96.77%。、SDS-PAGE、HPLC。125I-NGF125I-NGF、、20。2.3液相色谱-质谱联用技术LC-MS/MS-LC-MS/MSHPLCMS。ESIMALDI“”21。Liu45YNWNSFGLRF-NH254-。46NWNSFGLRF-NH25422。。AliciaSPE-HPLC-MS/MS23。2μm105kPaUPLCUPLC-MSPhylloseptinPSN-182%24。2.4活体成像技术Livinganimalimagingtechnology463。2.4.1核素活体成像技术PETSPECT。PETSPECT。Kamei68Ga-DOTA-insulinPETInsulin-CPPs。CPPs、25。2.4.2荧光标记技术、。FITC-BSAFITC-BSA。FITC-BSA26。2.5新型分析技术2.5.1电化学发光免疫分析ECLIAECLIAElectro-chemiluminescenceImmunoassay。Rubpy32+AbAg-AbRubpy32+Ag-Ab。LoweRanibizumab300pg/mL27。ECLIA、ELISALC-MS/MSPEG2.09~1258.52~75100~1000ng/mLECLIA28。2.5.2微流控芯片免疫分析方法。、、。Lin29PDMS4pmol/L。GyrosTM。LiuGyrosTMGyrosTM、ELISA30。3。、、。。、、、。ELISA。ELISA。、、。。6~81HPLC。。LC-MS/MS。、。LC-MS/MS、、。、、。、、、、。1XuHMYinRTChenXHetal.AnRGD-modifiedendostatin-derivedsyntheticpeptideshowsantitumoractivityinvivoJ.BioconjugateChem200819101980.2Alcala-BarrazaSRLeeMSHansonLRetal.IntranasaldeliveryofneurotrophicfactorsBDNFCNTFEPOandNT-4totheCNSJ.DrugTarget201018179.3KhafagyESMorishitaMKameiNetal.Efficiencyofcell-pene-tratingpeptidesonthenasalandintestinalabsorptionoftherapeu-ticpeptidesandproteinsJ.InterJPharmac200938149.4LiuS.RadiolabeledcyclicRGDpeptidesasintegrinαvβ3-targe-tedradiotracersmaximizingbindingaffinityviabivalencyJ.BioconjugChem2009202199.5WanXMChenYPXuWRetal.Dentificationofnose-to-brainhomingpeptidethroughphagedisplayJ.Peptides200920243.6CaiYZhangZFanFetal.Harmacokineticstissuedistribu-tionexcretionandantiviralactivityofpegylatedrecombinanthumanconsensusinterferon-alphavariantinmonkeysratsand563214guineapigsJ.RegulPept17374.7.PEGHM-3J.药物生物技术2011185416.8LuuKTBergqvistSChenEetal.Amodel-basedapproachtopredictingthehumanpharmacokineticsofamonoclonalantibodyexhibitingtaret-mediateddrugdispositionJ.JPharmacolExpTher2012341702.9UrvaSRBalthasarJP.TargetmediateddispositionofT84.66amonoclonalanti-CEAantibodyapplicationinthedetectionofcolorectalcancerxenograftsJ.Mabs20102167.10ZalevskyJChamberlainAKHortonHMetal.Enhancedanti-bodyhalf-lifeimprovesinvivoactivityJ.NatBiotechnol201028157.11StorkRZettlitzKARetherMetal.N-glycosylationasnovelstrategytoimprovepharmacokineticpropertiesofbispecificsin-gle-chaindiabodiesJ.JBiolChem20082837804.12LiYBXuHMHuJLetal.Quantitativeanalysisandpharmaco-kineticsstudyofintegrinantagonistAP25inratplasmaJ.Protein&Peptide.201320584.13.J.药学学报200035293.14BuurJLBaynesRESmithGWetal.Aphysiologicallybasedpharmacokineticmodellinkingplasmaproteinbindinginterac-tionswithdrugdispositionJ.ResVetSci2009126293.15DingYDJiangLChenLYetal.AsandwichELISAforassess-mentofpharmacokineticsofHSA-BNP2fusionproteininmouseplasmaJ.JPharmaceutBiomed201051658.16.间接包被ELISA法检测血清游离β-HCG方法学研究D.2010.17YinHHZhuYYXuLGetal.Ultrasensitivedetectionofmela-minebasedonaDNA-labeledimmunosensorJ.BiosensBioelec-tron20134251.18RobertEMArvindGK.Combineduseofimmunoassayandtwo-dimensionalliquidchromatographymassspectrometryforthedetectionandidentificationofmetabolitesfrombiotherapeuticpharmacokineticsamplesJ.JPharmaceutBiomed201053221.19.ADWX-1J.药物生物技术2012194334.20.125I-NGF、J.现代仪器201218110.21ArmandoARLudgerSRZaharenkoAJetal.Combiningmulti-dimensionalliquidchromatographyandMALDI-TOF-MSforthefingerprintanalysisofsecretedpeptidesfromtheunexploredseaanemonespeciesPhymanthuscruciferJ.JChromatogrB201290330.22LiuZFRenCJonesWetal.LC-MS/MSquantificationofaneuropeptidefragmentkisspeptin-10NSC741805andcharac-terizationofitsdecompositionproductandpharmacokineticsinratsJ.JChromatogrB20139261.23NavarreteAPazMMartínezAetal.SimultaneousonlineSPE-HPLC-MS/MSanalysisofdocetaxeltemsirolimusandsirolimusinwholebloodandhumanplasmaJ.JChromatogrB201392135.24ZhangRWLiuWTGengLLetal.Quantitativeanalysisofanovelantimicrobialpeptideinratplasmabyultraperformanceliquidchromatography-tandemmassspectrometryJ.JPharma-ceutBiomed201113191.25KameiaNMorishitaaMKanayamabY.Molecularimaginganaly-sisofintestinalinsulinabsorptionboostedbycell-penetratingpeptidesbyusingpositronemissiontomographyJ.JControllRelease2010146116.26.J.影像科学与光化学2010285354.27LoweJMaiaMWakshullEetal.Developmentofa
本文标题:蛋白多肽类药物体内药代动力学特征及分析方法研究进展
链接地址:https://www.777doc.com/doc-5219212 .html